Synopsis
Synopsis
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 847.0 g/mol |
---|---|
Molecular Formula | C46H62N4O11 |
XLogP3 | 6.3 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 5 |
Exact Mass | 846.44150881 g/mol |
Monoisotopic Mass | 846.44150881 g/mol |
Topological Polar Surface Area | 206 A^2 |
Heavy Atom Count | 61 |
Formal Charge | 0 |
Complexity | 1870 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 9 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 3 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Mycobutin |
PubMed Health | Rifabutin (By mouth) |
Drug Classes | Antitubercular |
Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
Active Ingredient | Rifabutin |
Dosage Form | Capsule |
Route | Oral |
Strength | 150mg |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
2 of 4 | |
---|---|
Drug Name | Rifabutin |
PubMed Health | Rifabutin (By mouth) |
Drug Classes | Antitubercular |
Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
Active Ingredient | Rifabutin |
Dosage Form | Capsule |
Route | Oral |
Strength | 150mg |
Market Status | Prescription |
Company | Lupin |
3 of 4 | |
---|---|
Drug Name | Rifabutin |
PubMed Health | Rifabutin (By mouth) |
Drug Classes | Antitubercular |
Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
Active Ingredient | Rifabutin |
Dosage Form | Capsule |
Route | Oral |
Strength | 150mg |
Market Status | Prescription |
Company | Lupin |
4 of 4 | |
---|---|
Drug Name | Mycobutin |
PubMed Health | Rifabutin (By mouth) |
Drug Classes | Antitubercular |
Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
Active Ingredient | Rifabutin |
Dosage Form | Capsule |
Route | Oral |
Strength | 150mg |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
60
PharmaCompass offers a list of Rifabutin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rifabutin manufacturer or Rifabutin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rifabutin manufacturer or Rifabutin supplier.
PharmaCompass also assists you with knowing the Rifabutin API Price utilized in the formulation of products. Rifabutin API Price is not always fixed or binding as the Rifabutin Price is obtained through a variety of data sources. The Rifabutin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Prestwick2_001109 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Prestwick2_001109, including repackagers and relabelers. The FDA regulates Prestwick2_001109 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Prestwick2_001109 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Prestwick2_001109 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Prestwick2_001109 supplier is an individual or a company that provides Prestwick2_001109 active pharmaceutical ingredient (API) or Prestwick2_001109 finished formulations upon request. The Prestwick2_001109 suppliers may include Prestwick2_001109 API manufacturers, exporters, distributors and traders.
click here to find a list of Prestwick2_001109 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Prestwick2_001109 DMF (Drug Master File) is a document detailing the whole manufacturing process of Prestwick2_001109 active pharmaceutical ingredient (API) in detail. Different forms of Prestwick2_001109 DMFs exist exist since differing nations have different regulations, such as Prestwick2_001109 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Prestwick2_001109 DMF submitted to regulatory agencies in the US is known as a USDMF. Prestwick2_001109 USDMF includes data on Prestwick2_001109's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Prestwick2_001109 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Prestwick2_001109 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Prestwick2_001109 Drug Master File in Korea (Prestwick2_001109 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Prestwick2_001109. The MFDS reviews the Prestwick2_001109 KDMF as part of the drug registration process and uses the information provided in the Prestwick2_001109 KDMF to evaluate the safety and efficacy of the drug.
After submitting a Prestwick2_001109 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Prestwick2_001109 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Prestwick2_001109 suppliers with KDMF on PharmaCompass.
A Prestwick2_001109 CEP of the European Pharmacopoeia monograph is often referred to as a Prestwick2_001109 Certificate of Suitability (COS). The purpose of a Prestwick2_001109 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Prestwick2_001109 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Prestwick2_001109 to their clients by showing that a Prestwick2_001109 CEP has been issued for it. The manufacturer submits a Prestwick2_001109 CEP (COS) as part of the market authorization procedure, and it takes on the role of a Prestwick2_001109 CEP holder for the record. Additionally, the data presented in the Prestwick2_001109 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Prestwick2_001109 DMF.
A Prestwick2_001109 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Prestwick2_001109 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Prestwick2_001109 suppliers with CEP (COS) on PharmaCompass.
A Prestwick2_001109 written confirmation (Prestwick2_001109 WC) is an official document issued by a regulatory agency to a Prestwick2_001109 manufacturer, verifying that the manufacturing facility of a Prestwick2_001109 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Prestwick2_001109 APIs or Prestwick2_001109 finished pharmaceutical products to another nation, regulatory agencies frequently require a Prestwick2_001109 WC (written confirmation) as part of the regulatory process.
click here to find a list of Prestwick2_001109 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Prestwick2_001109 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Prestwick2_001109 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Prestwick2_001109 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Prestwick2_001109 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Prestwick2_001109 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Prestwick2_001109 suppliers with NDC on PharmaCompass.
Prestwick2_001109 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Prestwick2_001109 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Prestwick2_001109 GMP manufacturer or Prestwick2_001109 GMP API supplier for your needs.
A Prestwick2_001109 CoA (Certificate of Analysis) is a formal document that attests to Prestwick2_001109's compliance with Prestwick2_001109 specifications and serves as a tool for batch-level quality control.
Prestwick2_001109 CoA mostly includes findings from lab analyses of a specific batch. For each Prestwick2_001109 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Prestwick2_001109 may be tested according to a variety of international standards, such as European Pharmacopoeia (Prestwick2_001109 EP), Prestwick2_001109 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Prestwick2_001109 USP).